Key Highlights
- Nuclera secures $75M in financing, led by Elevage Medical Technologies.
- eProtein Discovery system reduces protein production time to less than 48 hours.
- Investment supports US and European market expansion of eProtein Discovery system.
Source: Business Wire
Notable Quotes
- “This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made.” — Dr. Michael Chen, CEO at Nuclera
- “The demand for Nuclera’s technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development.” — Dr. Michael Wasserman, COO at Elevage Medical Technologies
- “The ability to screen multiple protein expression profiles and print purified proteins in as little as 24 hours will revolutionize laboratory workflows.” — Dr. Jonathan Milner, Chairman of the Board of Directors at Nuclera
SoHC's Take
Nuclera’s successful $75 million funding round underscores the increasing demand for solutions that can expedite the protein production process, particularly in drug discovery. The eProtein Discovery system offers a significant advantage by drastically reducing the time for protein expression, aligning well with advancements in AI-driven protein design. This positions Nuclera as a key player in the biotech space, catering to the growing need for faster, scalable protein production across industries. As AI and structural biology continue to evolve, Nuclera’s technology will likely become indispensable in life sciences and biopharma research globally.
